Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Ltd.BHVN · Entity 4379 | Director | April 28, 2026 | May 01, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | October 03, 2022 | October 03, 2022 |
| Serina Therapeutics, Inc.SER · Entity 9581 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Ltd.
Report date April 28, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28 | Direct | 68,693 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 2,583,658 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.94 · Expires 2030-04-29 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.24 · Expires 2029-05-20 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Serina Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,897,445 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Conversion · Acquired 1,770,805 · Balance 1,897,445 F1: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026. F2: The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 8,564,382 |
Reported balance
After 2026-06-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-17 · Conversion · Acquired 6,666,667 · Balance 8,564,382 F3: Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2036-06-17 | Direct | 15,250 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 15,250 · Balance 15,250 F4: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
| Redeemable WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2030-03-17 | Direct | 3,333,333 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Grant · Acquired 3,333,333 · Balance 3,333,333 F5: Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.18 | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-17 · Conversion · Disposed 762,548 · Balance 0 F6: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026.
F2: The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person.
F3: Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock.
F4: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
F5: Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice.
F6: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | ConversionSeries A Convertible Preferred Stock · Derivative | 762,548 | $2.25 Strike: $5.18 | $1,715,733.00 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · derivative · entry 5 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.0001 par value · 1,755,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantRedeemable Warrants · Derivative | 3,333,333 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · derivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,333,333 Underlying: Common Stock · 3,333,333 shares Expires 2030-03-17 F5 · shares: Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · derivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2036-06-17 F4 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | ConversionCommon Stock | 6,666,667 | $2.25 | $14,999,334.08 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,564,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | ConversionCommon Stock | 1,770,805 | $2.25 | $3,984,311.25 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,897,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026. F2 · balance_after: The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person. Read SEC document |
| April 28, 2026 Filed May 1, 2026 00:09 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 68,693 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001329505-26-000005 · wk-form4_1777594149.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,693 Underlying: Common Shares · 68,693 shares Expires 2036-04-28 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| March 31, 2026 Filed Apr 21, 2026 19:45 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantCommon Stock | 59,667 | $1.94 | $115,753.98 |
DisclosureSEC source: 0001329505-26-000002 · wk-form4_1776800739.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,910 F1 · shares: These shares of common stock were issued for payment of accrued dividends on the reporting individuals Series A Convertible Preferred Stock issued on April 8, 2025. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 12:31 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 400,000 | $7.50 | $3,000,000.00 |
DisclosureSEC source: 0001935979-25-000096 · wk-form4_1763382679.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,020,071 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 01:05 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001329505-25-000004 · wk-form4_1762823145.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-11-07 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| May 05, 2025 Filed May 7, 2025 21:14 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 31,716 | $0.00 Strike: $22.62 | $0.00 |
DisclosureSEC source: 0001935979-25-000045 · wk-form4_1746652465.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716 Underlying: Common Shares · 31,716 shares Expires 2035-05-05 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2026 or (b) the date of the 2026 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 20:02 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantSeries A Convertible Preferred Stock · Derivative | 762,548 | $5.18 Strike: $5.18 | $3,949,998.64 |
DisclosureSEC source: 0001708599-25-000037 · wk-form4_1744315352.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 762,548 Underlying: Common Stock, $0.0001 par value · 762,548 shares Expires not disclosed F1 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:05 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 3,866 | $4.59 | $17,744.55 |
DisclosureSEC source: 0001493152-24-050774 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,243 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $4.54 per share to a high of $4.74 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 11:30 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 5,000 | $44.19 | $220,966.00 |
DisclosureSEC source: 0001935979-24-000075 · wk-form4_1727263813.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,620,071 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.13 - $44.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 20:30 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,137 | $6.03 | $6,851.45 |
DisclosureSEC source: 0001493152-24-037965 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,377 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $5.74 per share to a high of $6.25 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 22:59 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 11,679 | $6.11 | $71,384.38 |
DisclosureSEC source: 0001493152-24-037714 · ownership.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,240 F2 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $5.96 per share to a high of $6.25 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 22:59 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 2,709 | $6.23 | $16,873.01 |
DisclosureSEC source: 0001493152-24-037714 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,561 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $6.18 per share to a high of $6.25 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 21:27 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,776 | $8.25 | $14,652.00 |
DisclosureSEC source: 0001493152-24-033599 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,582 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $8.00 per share to a high of $8.88 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 6,400 | $7.93 | $50,760.32 |
DisclosureSEC source: 0001493152-24-033277 · ownership.xml · nonDerivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,806 F3 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $7.24 per share to a high of $8.57 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 6,400 | $7.31 | $46,779.52 |
DisclosureSEC source: 0001493152-24-033277 · ownership.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,406 F2 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $7.12 per share to a high of $8.02 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 20:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 6,400 | $6.65 | $42,576.64 |
DisclosureSEC source: 0001493152-24-033277 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,006 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $6.55 per share to a high of $7.94 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:20 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 6,400 | $7.07 | $45,228.16 |
DisclosureSEC source: 0001493152-24-032829 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,606 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low of $6.83 per share to a high of $7.35 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:18 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 5,205 | $9.50 | $49,447.50 |
DisclosureSEC source: 0001493152-24-022200 · ownership.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,206 Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:18 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,173 | $9.50 | $11,143.50 |
DisclosureSEC source: 0001493152-24-022200 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,001 Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:15 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 9,019 | $9.50 | $85,680.50 |
DisclosureSEC source: 0001493152-24-021786 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,828 Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:15 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 2,371 | $9.50 | $22,524.50 |
DisclosureSEC source: 0001493152-24-021358 · ownership.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,809 Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:15 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,422 | $9.50 | $13,509.00 |
DisclosureSEC source: 0001493152-24-021148 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,522 Read SEC document |
| May 21, 2024 Filed May 24, 2024 20:15 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 916 | $9.50 | $8,702.00 |
DisclosureSEC source: 0001493152-24-021358 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,438 Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:15 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 100 | $9.00 | $900.00 |
DisclosureSEC source: 0001493152-24-021013 · ownership.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100 Read SEC document |
| May 13, 2024 Filed May 15, 2024 11:31 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 15,000 | $34.19 | $512,877.00 |
DisclosureSEC source: 0001562180-24-004045 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,615,071 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.11 - $34.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003749 · primarydocument.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 24, 2024 Filed Apr 25, 2024 11:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 25,503 | $39.18 | $999,169.29 |
DisclosureSEC source: 0001562180-24-003521 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600,071 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.13 - $39.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 48,780 | $41.00 | $1,999,980.00 |
DisclosureSEC source: 0001562180-24-003495 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,574,568 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 21:18 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001493152-24-013225 · ownership.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,691 Underlying: Common Stock · 40,000 shares Expires 2034-04-01 F1 · derivative.exercise_date: The stock options vest in three equal installments on April 1, 2025, April 1, 2026 and April 1, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · balance_after: Number of derivative securities determined after giving effect to a reverse split of the Issuer's common stock of 1-for-35.17. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 11:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 17,817 | $22.57 | $402,094.06 |
DisclosureSEC source: 0001562180-23-007228 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,525,788 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.435 - $22.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:52 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 52,906 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001562180-23-003946 · primarydocument.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,906 Underlying: Common Shares · 52,906 shares Expires 2033-05-02 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 2, 2024 or (b) the date of the 2024 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| October 25, 2022 Filed Oct 26, 2022 22:22 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 200,000 | $10.50 | $2,100,000.00 |
DisclosureSEC source: 0001562180-22-007335 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507,971 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:23 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $60.24 | Not disclosed |
DisclosureSEC source: 0001562180-22-006953 · primarydocument.xml · derivative · entry 5 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,000 shares Expires 2029-05-20 F3 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:23 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $45.94 | Not disclosed |
DisclosureSEC source: 0001562180-22-006953 · primarydocument.xml · derivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,000 shares Expires 2030-04-29 F3 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:23 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 11,996 | Not disclosed Strike: $70.17 | Not disclosed |
DisclosureSEC source: 0001562180-22-006953 · primarydocument.xml · derivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 11,996 shares Expires 2031-05-05 F3 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:23 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 8,239 | Not disclosed Strike: $95.33 | Not disclosed |
DisclosureSEC source: 0001562180-22-006953 · primarydocument.xml · derivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,239 shares Expires 2032-04-28 F3 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:23 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerCommon Shares | 2,583,658 | $148.50 | $383,673,213.00 |
DisclosureSEC source: 0001562180-22-006953 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 15 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F4 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 14 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,000 shares Expires 2029-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 13 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,000 shares Expires 2030-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,998 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 12 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to buy) · Derivative | 4,119 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 11 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 9,000 | Not disclosed Strike: $3.06 | Not disclosed |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 10 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2029-05-20 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 9,000 | Not disclosed Strike: $2.33 | Not disclosed |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 9 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2030-04-29 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 5,998 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 8 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 4,119 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 7 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.